Table 3.
Metabolites altered between study groups in the general offspring.
| Metabolites | VIP | FC | P value | Trend |
|---|---|---|---|---|
| Glycerolipids [GL] | ||||
| MG (0:0/20:4(8Z,11Z,14Z,17Z)/0:0) | 1.51 | 1.33 | 0.05 | ↑ |
| Monoelaidin | 1.51 | 0.78 | 0.001 | ↓ |
| DG (14:0/16:0/0:0) | 2.26 | 0.75 | 0.02 | ↓ |
| DG (14:0/18:2(9Z,12Z)/0:0) | 1.66 | 0.77 | 0.01 | ↓ |
| DG (14:1(9Z)/16:0/0:0) | 2.95 | 0.68 | 0.02 | ↓ |
| DG (15:0/18:1(11Z)/0:0) | 4.59 | 0.62 | 0.05 | ↓ |
| DG (16:0/16:1(9Z)/0:0) | 2.27 | 0.71 | 0.05 | ↓ |
| DG (16:1(9Z)/16:0/0:0) | 1.42 | 0.78 | 0.02 | ↓ |
| DG (16:1(9Z)/18:3(9Z,12Z,15Z)/0:0) | 1.62 | 0.70 | 0.001 | ↓ |
| TG (12:0/14:0/18:1(9Z)) [iso6] | 3.18 | 0.54 | 0.04 | ↓ |
| TG (12:0/16:0/18:1(9Z)) [iso6] | 3.17 | 0.63 | 0.04 | ↓ |
| TG (12:0/16:1(9Z)/18:2(9Z,12Z)) [iso6] | 3.20 | 0.71 | 0.02 | ↓ |
| TG (14:0/18:2(9Z,12Z)/16:1(9Z)) | 2.25 | 0.73 | 0.02 | ↓ |
| TG (15:0/18:1(9Z)/16:1(9Z)) [iso6] | 1.77 | 0.75 | 0.04 | ↓ |
| TG (15:0/18:1(9Z)/18:1(9Z)) [iso3] | 1.10 | 0.82 | 0.02 | ↓ |
| TG (16:0/14:0/18:1(9Z)) [iso6] | 2.14 | 0.73 | 0.05 | ↓ |
| TG (16:0/14:0/18:2(9Z,12Z)) [iso6] | 2.17 | 0.76 | 0.05 | ↓ |
| TG (16:0/15:0/18:1(11Z)) | 2.24 | 0.76 | 0.01 | ↓ |
| TG (16:1(9Z)/18:4(6Z,9Z,12Z,15Z)/18:1(11Z)) | 1.15 | 0.83 | 0.04 | ↓ |
| TG (18:2(9Z,12Z)/14:0/18:3(9Z,12Z,15Z)) [iso6] | 1.70 | 0.80 | 0.02 | ↓ |
| Glycerophospholipids [GP] | ||||
| PA (P-16:0/18:1(9Z)) | 1.17 | 0.80 | 0.01 | ↓ |
| PA (O-16:0/14:0) | 1.05 | 0.77 | 0.02 | ↓ |
| PC (o-18:0/22:0) | 3.70 | 1.32 | 0.001 | ↑ |
| PC (13:0/0:0) | 3.97 | 0.76 | 0.02 | ↓ |
| PI (18:3(9Z,12Z,15Z)/16:0) | 3.93 | 0.73 | 0.01 | ↓ |
| LysoPE (0:0/18:0) | 2.15 | 0.81 | 0.02 | ↓ |
| LysoPC (14:0) | 3.45 | 0.75 | 0.02 | ↓ |
| Fatty Acyls [FA] | ||||
| 1-Tridecene | 2.23 | 0.79 | 0.002 | ↓ |
| 2-Linoleoylglycerol | 1.49 | 0.76 | 0.01 | ↓ |
| cis-Uvariamicin IB | 7.28 | 1.69 | 0.02 | ↑ |
| Hexacosanoyl carnitine | 2.19 | 1.29 | 0.001 | ↑ |
| Methyl jasmonate | 4.00 | 0.75 | 0.04 | ↓ |
| Carboxylic acids and derivatives | ||||
| L-Glutamine | 1.84 | 0.83 | 0.01 | ↓ |
| Rhizonin A | 1.48 | 0.80 | 0.01 | ↓ |
| N-Nonanoylglycine | 3.62 | 0.71 | 0.05 | ↓ |
| Benzene and substituted derivatives | ||||
| 3-Pentadecylphenol | 1.43 | 1.20 | 0.01 | ↑ |
| 2-Hydroxybenzaldehyde | 2.69 | 1.22 | 0.003 | ↑ |
| Prenol Lipids [PR] | ||||
| Coenzyme Q10 | 1.12 | 1.20 | 0.003 | ↑ |
| Sphingolipids [SP] | ||||
| SM (d16:1/23:0) | 1.82 | 1.22 | 0.001 | ↑ |
| Unclassified metabolites | ||||
| Endosulfan-sulfate | 1.84 | 1.22 | 0.02 | ↑ |
| bacteriohopane-31,32,33,34,35-pentol | 2.97 | 0.70 | 0.02 | ↓ |
| Progesterone, 16.alpha.-methyl- | 1.05 | 0.82 | 0.04 | ↓ |
| (24R)-25-fluoro-1alpha,24-dihydroxyvitamin D3 | 2.78 | 0.78 | 0.01 | ↓ |
| 12,13-DHOME | 3.28 | 0.76 | 0.04 | ↓ |
The threshold value was VIP > 1.0, FC > 1.2 or FC < 0.833 and P value < 0.05.
The potential markers with clinical value were presented in bold.
VIP, variable importance in the projection value from PLS-DA model; FC, fold change; P value was calculated by student t test.